Obinutuzumab in Chinese Real-world Patients With iNHL

Efficacy and Safety of Obinutuzumab in Chinese Patients With Indolent Non-Hodgkin's B-cell Lymphoma in the Real-World.

This study aims to assess the clinical efficacy and safety of obinutuzumab in Chinese patients with indolent non-Hodgkin B-cell Lymphoma (predominantly Follicular lymphoma and Marginal zone lymphoma) in a real-world setting.

This study was a prospective, multicenter, non-interventional, real-world study. The study will be divided into two cohorts: Cohort 1 is the younger cohort (aged ≥ 18 and < 60 years at the start of treatment); Cohort 2 is the older cohort (aged ≥ 60 years at the start of treatment). Patients in this study will receive obinutuzumab-contained regimens according to the investigators' clinical opinion.

Inclusion Criteria:

• Age: Age ≥ 18 years at the start of treatment;
• Be diagnosed with grade 1-3a follicular Lymphoma, Marginal zone lymphoma;
• Previously untreated or relapsed or refractory patients;
• Patients who started treatment with otuzumab between June 2021 and April 2023.

Exclusion Criteria:

• Patients currently participating or planning to participate in any interventional clinical trial;
• Patients who, in the opinion of the investigator, are Discomfort for any other reason to participate in this study.